Secukinumab provides sustained low rates of radiographic progression in psoriatic arthritis: 52-week results from a phase 3 study, FUTURE 5

OBJECTIVE: To evaluate the effect of secukinumab on radiographic progression through 52 weeks in patients with PsA from the FUTURE 5 study. METHODS: Patients with active PsA, stratified by prior anti-TNF use (naïve or inadequate response), were randomized to s.c. secukinumab 300 mg load (300 mg), 15...

Descripción completa

Detalles Bibliográficos
Autores principales: van der Heijde, Désirée, Mease, Philip J, Landewé, Robert B M, Rahman, Proton, Tahir, Hasan, Singhal, Atul, Boettcher, Elke, Navarra, Sandra, Zhu, Xuan, Ligozio, Gregory, Readie, Aimee, Mpofu, Shephard, Pricop, Luminita
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Clinical Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7244782/
https://www.ncbi.nlm.nih.gov/pubmed/31586420
http://dx.doi.org/10.1093/rheumatology/kez420

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7244782/
https://www.ncbi.nlm.nih.gov/pubmed/31586420
http://dx.doi.org/10.1093/rheumatology/kez420

Ejemplares similares